On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – PsyBio Therapeutics Inc. and Miami University Researchers Collaborate to Develop Exciting Class of Molecules to Treat Mental Health Challenges, Substance Dependency

Company: PsyBio Therapeutics Inc.
Category: News

PsyBio Therapeutics (“PsyBio”) and Miami University in Oxford, Ohio are collaborating to develop a new and exciting class of molecules to treat mental health challenges such as depression, anxiety, PTSD, and substance dependency. According to the update, PsyBio has agreed to a two-year research sponsorship with Miami University in further development of a platform technology that enables the biosynthesis of psilocybin and other psychoactive molecules that occur naturally in certain plants and fungi. Miami has additionally granted PsyBio a global exclusive license to the technology generated from such research. “We are excited to be working in collaboration with such a prestigious research university,” PsyBio Therapeutics CEO Evan Levine stated in the news release. “PsyBio Therapeutics was launched in response to the growing unmet medical need and demand to offer a new paradigm for the treatment of mental health issues and other healthcare challenges. The therapeutic candidates that we are developing are intended to heal the patient and treat the disease, in comparison to many drugs on the market that only address the symptoms and not the underlying cause.”

To view the full press release, visit http://nnw.fm/d9J0R

About PsyBio Therapeutics

PsyBio Therapeutics is developing biosynthetic psychoactive compounds that offer a new paradigm of treatment to reverse the course of mental health issues. Psychoactive medications treat the illness by rewiring the brain through contemplation and a change of perception in combination with psychotherapy vs. standard of care (SSRIs, SNRIs, MAOIs, NDRIs, etc.), which just chemically treat symptoms. PsyBio Therapeutics is working in collaboration with Miami University utilizing a proprietary platform technology to biologically synthesize psilocybin and other targeted next-generation active compounds in Psilocybe Cubensis and other fungi and plants. For more information, visit www.PsyBioLife.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217